Promotional content developed and funded by Novartis Pharmaceuticals UK Ltd
for UK healthcare professionals only

Prescribing information Adverse event reporting information 

INGRAIN-MF
Incorporating genetics, risk and associated burden into MF management

MODULE 1: The burden of myelofibrosis

Introduction

Myelofibrosis (MF), a myeloproliferative neoplasm, is a rare and life-limiting blood disorder in which bone marrow fibrosis affects haematopoiesis. It is a heterogeneous disease, associated with features including abnormal blood count (in particular anaemia), splenomegaly and severe constitutional symptoms, as well as leukaemic transformation and early mortality.1,2

In this module, you will learn about:

  • survival and transformation rates in MF
  • diagnostic criteria, including bone marrow biopsy, blood tests and clinical features
  • the symptom burden on patients, whether it is under-recognised, and how it affects quality of life
  • objective monitoring of symptoms

Multiple-choice questions (MCQs) to test your current knowledge

These MCQs will help you assess your current knowledge of this topic before you begin to work through the module. Your answers will be marked but will not count towards your final score. You will be asked the same MCQs at the end of the module. You will be able to download a learning certificate for your records upon completion.

MPN: myeloproliferative neoplasm

Continue 
Homepage

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

References
  1. Cervantes F, Dupriez B et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113(13):2895-2901.
  2. Harrison C N, Mead A J et al. A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK. Br J Haematol 2020;188(6):e105-e109.